Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35,320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring.
Brady T, Zhang T, Tuffy KM, Haskins N, Du Q, Lin J, Kaplan G, Novick S, Roe TL, Ren K, Rosenthal K, McTamney PM, Abram ME, Streicher K, Kelly EJ. Brady T, et al. Among authors: zhang t. Microbiol Spectr. 2022 Oct 26;10(5):e0103422. doi: 10.1128/spectrum.01034-22. Epub 2022 Aug 22. Microbiol Spectr. 2022. PMID: 35993765 Free PMC article.
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
Tuffy KM, Ahani B, Aksyuk AA, Avila M, Brady T, Kijak GH, Koh G, Levin MJ, Roe TL, Schuko N, Thissen J, Ustianowski A, Zhang T, Kelly EJ, Streicher K. Tuffy KM, et al. Among authors: zhang t. J Infect Dis. 2023 Oct 18;228(8):1055-1059. doi: 10.1093/infdis/jiad210. J Infect Dis. 2023. PMID: 37280116 Free PMC article. Clinical Trial.
Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
Wilkins D, Yuan Y, Chang Y, Aksyuk AA, Núñez BS, Wählby-Hamrén U, Zhang T, Abram ME, Leach A, Villafana T, Esser MT. Wilkins D, et al. Among authors: zhang t. Nat Med. 2024 Apr 22. doi: 10.1038/s41591-024-03006-6. Online ahead of print. Nat Med. 2024. PMID: 38649782 No abstract available.
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
Kijak GH, Ahani B, Arbetter D, Chuecos F, Gopalakrishnan V, Beloor J, Brady T, Nguyen A, Roe TL, Schuko N, Zhang T, Hobbs FDR, Padilla F, Kelly EJ, Montgomery H, Streicher K. Kijak GH, et al. Among authors: zhang t. Infect Dis Ther. 2023 Dec;12(12):2691-2707. doi: 10.1007/s40121-023-00882-2. Epub 2023 Nov 2. Infect Dis Ther. 2023. PMID: 37914983 Free PMC article.
35,320 results
You have reached the last available page of results. Please see the User Guide for more information.